http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 04 Aug 2026 16:50:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alpha+Cognition+Inc.++++++For%3A+Jul+31++Filed+by%3A+Opaleye+Management+Inc./26867463.html si-local-file:///var/storage/secattach/20260804/26867463.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alpha+Cognition+Inc.++++++For%3A+Jul+31++Filed+by%3A+Opaleye+Management+Inc./26867463.html Tue, 04 Aug 2026 16:50:00 -0400 ACOG O.40625266 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alpha+Cognition+Inc.++++++For%3A+Jul+31++Filed+by%3A+Opaleye+Management+Inc./26867463.html si-local-file:///var/storage/secattach/20260804/26867463.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alpha+Cognition+Inc.++++++For%3A+Jul+31++Filed+by%3A+Opaleye+Management+Inc./26867463.html Tue, 04 Aug 2026 16:50:00 -0400 ACOG O.40625266 http://www.streetinsider.com/Press+Releases/Alpha+Cognition+to+Report+Second+Quarter+2026+Financial+Results+and+Provide+Business+Update/26854434.html <p> VANCOUVER, British Columbia &amp; DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, at 4:30 p.m. ET, after market close. </p><p> The company will issue a press release detailing its second quarter financial results and business highlights on that date. The financial results and accompanying materials will be available in the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.alphacognition.com%2Finvestors%2Fnews%2F&amp;esheet=54580592&amp;newsitemid=20260803960737&amp;lan=en-US&amp;anchor=News&amp;index=1&amp;md5=e1e497cd63af4224465f70f4f00f283c" shape="rect">News</a> section of the Alpha Cognition website. </p><p> Following the release, management will host a conference http://www.streetinsider.com/Press+Releases/Alpha+Cognition+to+Report+Second+Quarter+2026+Financial+Results+and+Provide+Business+Update/26854434.html Mon, 03 Aug 2026 08:30:00 -0400 ACOG O.40625266 http://www.streetinsider.com/Press+Releases/Alpha+Cognition+to+Report+Second+Quarter+2026+Financial+Results+and+Provide+Business+Update/26854434.html <p> VANCOUVER, British Columbia &amp; DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, at 4:30 p.m. ET, after market close. </p><p> The company will issue a press release detailing its second quarter financial results and business highlights on that date. The financial results and accompanying materials will be available in the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.alphacognition.com%2Finvestors%2Fnews%2F&amp;esheet=54580592&amp;newsitemid=20260803960737&amp;lan=en-US&amp;anchor=News&amp;index=1&amp;md5=e1e497cd63af4224465f70f4f00f283c" shape="rect">News</a> section of the Alpha Cognition website. </p><p> Following the release, management will host a conference http://www.streetinsider.com/Press+Releases/Alpha+Cognition+to+Report+Second+Quarter+2026+Financial+Results+and+Provide+Business+Update/26854434.html Mon, 03 Aug 2026 08:30:00 -0400 ACOG O.40625266 http://www.streetinsider.com/Business+Wire/Alpha+Cognition+to+Report+Second+Quarter+2026+Financial+Results+and+Provide+Business+Update/26854434.html <p> VANCOUVER, British Columbia &amp; DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, at 4:30 p.m. ET, after market close. </p><p> The company will issue a press release detailing its second quarter financial results and business highlights on that date. The financial results and accompanying materials will be available in the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.alphacognition.com%2Finvestors%2Fnews%2F&amp;esheet=54580592&amp;newsitemid=20260803960737&amp;lan=en-US&amp;anchor=News&amp;index=1&amp;md5=e1e497cd63af4224465f70f4f00f283c" shape="rect">News</a> section of the Alpha Cognition website. </p><p> Following the release, management will host a conference http://www.streetinsider.com/Business+Wire/Alpha+Cognition+to+Report+Second+Quarter+2026+Financial+Results+and+Provide+Business+Update/26854434.html Mon, 03 Aug 2026 08:30:00 -0400 ACOG O.40625266 http://www.streetinsider.com/Business+Wire/Alpha+Cognition+to+Report+Second+Quarter+2026+Financial+Results+and+Provide+Business+Update/26854434.html <p> VANCOUVER, British Columbia &amp; DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, at 4:30 p.m. ET, after market close. </p><p> The company will issue a press release detailing its second quarter financial results and business highlights on that date. The financial results and accompanying materials will be available in the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.alphacognition.com%2Finvestors%2Fnews%2F&amp;esheet=54580592&amp;newsitemid=20260803960737&amp;lan=en-US&amp;anchor=News&amp;index=1&amp;md5=e1e497cd63af4224465f70f4f00f283c" shape="rect">News</a> section of the Alpha Cognition website. </p><p> Following the release, management will host a conference http://www.streetinsider.com/Business+Wire/Alpha+Cognition+to+Report+Second+Quarter+2026+Financial+Results+and+Provide+Business+Update/26854434.html Mon, 03 Aug 2026 08:30:00 -0400 ACOG O.40625266 http://www.streetinsider.com/Corporate+News/Alpha+Cognition+receives+European+patent+for+Alzheimer%27s+drug+Zunveyl/26831184.html <p>Alpha Cognition Inc. (NASDAQ: ACOG) announced that the European Patent Office has granted a patent covering a crystalline solid form of benzgalantamine, the active ingredient in its Alzheimer's drug Zunveyl, for the treatment of mild-to-moderate Alzheimer's disease.</p><p>The patent includes claims directed to the crystalline solid form, related pharmaceutical compositions, preparations, methods of manufacture, and medical-use claims. The company said the grant may provide patent protection for benzgalantamine through 2042, subject to applicable patent requirements.</p><p>The patent may be validated in European Patent Convention member states, covering both European Union and non-EU jurisdictions such as Switzerland and the United Kingdom.</p><p>"This European patent http://www.streetinsider.com/Corporate+News/Alpha+Cognition+receives+European+patent+for+Alzheimer%27s+drug+Zunveyl/26831184.html Wed, 29 Jul 2026 08:30:33 -0400 ACOG http://www.streetinsider.com/Press+Releases/Alpha+Cognition+Receives+European+Patent+Covering+ZUNVEYL%C2%AE+for+the+Treatment+of+Mild-to-Moderate+Alzheimer%E2%80%99s+Disease/26831154.html <p> VANCOUVER, British Columbia &amp; GRAPEVINE, Texas--(BUSINESS WIRE)-- <b>Alpha Cognition Inc. (NASDAQ: ACOG) </b>(“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that the European Patent Office (EPO) has granted a patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in the treatment of mild-to-moderate Alzheimer’s disease. </p><p> The patent includes claims directed to the specific crystalline solid form, related pharmaceutical compositions, preparations, methods of manufacture and medical-use claims. The grant further strengthens Alpha Cognition’s global intellectual property portfolio and may provide additional patent protection http://www.streetinsider.com/Press+Releases/Alpha+Cognition+Receives+European+Patent+Covering+ZUNVEYL%C2%AE+for+the+Treatment+of+Mild-to-Moderate+Alzheimer%E2%80%99s+Disease/26831154.html Wed, 29 Jul 2026 08:30:00 -0400 A.03718595 ACOG O.04906507 O.40625266 http://www.streetinsider.com/Press+Releases/Alpha+Cognition+Receives+European+Patent+Covering+ZUNVEYL%C2%AE+for+the+Treatment+of+Mild-to-Moderate+Alzheimer%E2%80%99s+Disease/26831154.html <p> VANCOUVER, British Columbia &amp; GRAPEVINE, Texas--(BUSINESS WIRE)-- <b>Alpha Cognition Inc. (NASDAQ: ACOG) </b>(“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that the European Patent Office (EPO) has granted a patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in the treatment of mild-to-moderate Alzheimer’s disease. </p><p> The patent includes claims directed to the specific crystalline solid form, related pharmaceutical compositions, preparations, methods of manufacture and medical-use claims. The grant further strengthens Alpha Cognition’s global intellectual property portfolio and may provide additional patent protection http://www.streetinsider.com/Press+Releases/Alpha+Cognition+Receives+European+Patent+Covering+ZUNVEYL%C2%AE+for+the+Treatment+of+Mild-to-Moderate+Alzheimer%E2%80%99s+Disease/26831154.html Wed, 29 Jul 2026 08:30:00 -0400 A.03718595 ACOG O.04906507 O.40625266 http://www.streetinsider.com/Press+Releases/Alpha+Cognition+Receives+European+Patent+Covering+ZUNVEYL%C2%AE+for+the+Treatment+of+Mild-to-Moderate+Alzheimer%E2%80%99s+Disease/26831154.html <p> VANCOUVER, British Columbia &amp; GRAPEVINE, Texas--(BUSINESS WIRE)-- <b>Alpha Cognition Inc. (NASDAQ: ACOG) </b>(“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that the European Patent Office (EPO) has granted a patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in the treatment of mild-to-moderate Alzheimer’s disease. </p><p> The patent includes claims directed to the specific crystalline solid form, related pharmaceutical compositions, preparations, methods of manufacture and medical-use claims. The grant further strengthens Alpha Cognition’s global intellectual property portfolio and may provide additional patent protection http://www.streetinsider.com/Press+Releases/Alpha+Cognition+Receives+European+Patent+Covering+ZUNVEYL%C2%AE+for+the+Treatment+of+Mild-to-Moderate+Alzheimer%E2%80%99s+Disease/26831154.html Wed, 29 Jul 2026 08:30:00 -0400 A.03718595 ACOG O.04906507 O.40625266 http://www.streetinsider.com/Press+Releases/Alpha+Cognition+Receives+European+Patent+Covering+ZUNVEYL%C2%AE+for+the+Treatment+of+Mild-to-Moderate+Alzheimer%E2%80%99s+Disease/26831154.html <p> VANCOUVER, British Columbia &amp; GRAPEVINE, Texas--(BUSINESS WIRE)-- <b>Alpha Cognition Inc. (NASDAQ: ACOG) </b>(“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that the European Patent Office (EPO) has granted a patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in the treatment of mild-to-moderate Alzheimer’s disease. </p><p> The patent includes claims directed to the specific crystalline solid form, related pharmaceutical compositions, preparations, methods of manufacture and medical-use claims. The grant further strengthens Alpha Cognition’s global intellectual property portfolio and may provide additional patent protection http://www.streetinsider.com/Press+Releases/Alpha+Cognition+Receives+European+Patent+Covering+ZUNVEYL%C2%AE+for+the+Treatment+of+Mild-to-Moderate+Alzheimer%E2%80%99s+Disease/26831154.html Wed, 29 Jul 2026 08:30:00 -0400 A.03718595 ACOG O.04906507 O.40625266 http://www.streetinsider.com/Business+Wire/Alpha+Cognition+Receives+European+Patent+Covering+ZUNVEYL%C2%AE+for+the+Treatment+of+Mild-to-Moderate+Alzheimer%E2%80%99s+Disease/26831154.html <p> VANCOUVER, British Columbia &amp; GRAPEVINE, Texas--(BUSINESS WIRE)-- <b>Alpha Cognition Inc. (NASDAQ: ACOG) </b>(“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that the European Patent Office (EPO) has granted a patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in the treatment of mild-to-moderate Alzheimer’s disease. </p><p> The patent includes claims directed to the specific crystalline solid form, related pharmaceutical compositions, preparations, methods of manufacture and medical-use claims. The grant further strengthens Alpha Cognition’s global intellectual property portfolio and may provide additional patent protection http://www.streetinsider.com/Business+Wire/Alpha+Cognition+Receives+European+Patent+Covering+ZUNVEYL%C2%AE+for+the+Treatment+of+Mild-to-Moderate+Alzheimer%E2%80%99s+Disease/26831154.html Wed, 29 Jul 2026 08:30:00 -0400 A.03718595 ACOG O.04906507 O.40625266 http://www.streetinsider.com/Business+Wire/Alpha+Cognition+Receives+European+Patent+Covering+ZUNVEYL%C2%AE+for+the+Treatment+of+Mild-to-Moderate+Alzheimer%E2%80%99s+Disease/26831154.html <p> VANCOUVER, British Columbia &amp; GRAPEVINE, Texas--(BUSINESS WIRE)-- <b>Alpha Cognition Inc. (NASDAQ: ACOG) </b>(“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that the European Patent Office (EPO) has granted a patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in the treatment of mild-to-moderate Alzheimer’s disease. </p><p> The patent includes claims directed to the specific crystalline solid form, related pharmaceutical compositions, preparations, methods of manufacture and medical-use claims. The grant further strengthens Alpha Cognition’s global intellectual property portfolio and may provide additional patent protection http://www.streetinsider.com/Business+Wire/Alpha+Cognition+Receives+European+Patent+Covering+ZUNVEYL%C2%AE+for+the+Treatment+of+Mild-to-Moderate+Alzheimer%E2%80%99s+Disease/26831154.html Wed, 29 Jul 2026 08:30:00 -0400 A.03718595 ACOG O.04906507 O.40625266 http://www.streetinsider.com/Business+Wire/Alpha+Cognition+Receives+European+Patent+Covering+ZUNVEYL%C2%AE+for+the+Treatment+of+Mild-to-Moderate+Alzheimer%E2%80%99s+Disease/26831154.html <p> VANCOUVER, British Columbia &amp; GRAPEVINE, Texas--(BUSINESS WIRE)-- <b>Alpha Cognition Inc. (NASDAQ: ACOG) </b>(“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that the European Patent Office (EPO) has granted a patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in the treatment of mild-to-moderate Alzheimer’s disease. </p><p> The patent includes claims directed to the specific crystalline solid form, related pharmaceutical compositions, preparations, methods of manufacture and medical-use claims. The grant further strengthens Alpha Cognition’s global intellectual property portfolio and may provide additional patent protection http://www.streetinsider.com/Business+Wire/Alpha+Cognition+Receives+European+Patent+Covering+ZUNVEYL%C2%AE+for+the+Treatment+of+Mild-to-Moderate+Alzheimer%E2%80%99s+Disease/26831154.html Wed, 29 Jul 2026 08:30:00 -0400 A.03718595 ACOG O.04906507 O.40625266 http://www.streetinsider.com/Business+Wire/Alpha+Cognition+Receives+European+Patent+Covering+ZUNVEYL%C2%AE+for+the+Treatment+of+Mild-to-Moderate+Alzheimer%E2%80%99s+Disease/26831154.html <p> VANCOUVER, British Columbia &amp; GRAPEVINE, Texas--(BUSINESS WIRE)-- <b>Alpha Cognition Inc. (NASDAQ: ACOG) </b>(“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that the European Patent Office (EPO) has granted a patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in the treatment of mild-to-moderate Alzheimer’s disease. </p><p> The patent includes claims directed to the specific crystalline solid form, related pharmaceutical compositions, preparations, methods of manufacture and medical-use claims. The grant further strengthens Alpha Cognition’s global intellectual property portfolio and may provide additional patent protection http://www.streetinsider.com/Business+Wire/Alpha+Cognition+Receives+European+Patent+Covering+ZUNVEYL%C2%AE+for+the+Treatment+of+Mild-to-Moderate+Alzheimer%E2%80%99s+Disease/26831154.html Wed, 29 Jul 2026 08:30:00 -0400 A.03718595 ACOG O.04906507 O.40625266 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alpha+Cognition+Inc.++++++For%3A+Jul+24++Filed+by%3A+Opaleye+Management+Inc./26827024.html si-local-file:///var/storage/secattach/20260728/26827024.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alpha+Cognition+Inc.++++++For%3A+Jul+24++Filed+by%3A+Opaleye+Management+Inc./26827024.html Tue, 28 Jul 2026 16:05:00 -0400 ACOG O.40625266 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alpha+Cognition+Inc.++++++For%3A+Jul+24++Filed+by%3A+Opaleye+Management+Inc./26827024.html si-local-file:///var/storage/secattach/20260728/26827024.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alpha+Cognition+Inc.++++++For%3A+Jul+24++Filed+by%3A+Opaleye+Management+Inc./26827024.html Tue, 28 Jul 2026 16:05:00 -0400 ACOG O.40625266 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alpha+Cognition+Inc.++++++For%3A+Jul+22++Filed+by%3A+Opaleye+Management+Inc./26813540.html si-local-file:///var/storage/secattach/20260724/26813540.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alpha+Cognition+Inc.++++++For%3A+Jul+22++Filed+by%3A+Opaleye+Management+Inc./26813540.html Fri, 24 Jul 2026 16:05:00 -0400 ACOG O.40625266 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alpha+Cognition+Inc.++++++For%3A+Jul+22++Filed+by%3A+Opaleye+Management+Inc./26813540.html si-local-file:///var/storage/secattach/20260724/26813540.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alpha+Cognition+Inc.++++++For%3A+Jul+22++Filed+by%3A+Opaleye+Management+Inc./26813540.html Fri, 24 Jul 2026 16:05:00 -0400 ACOG O.40625266 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Alpha+Cognition+Inc.+++++++++++++++++++Filed+by%3A+Opaleye+Management+Inc./26813547.html si-local-file:///var/storage/secattach/20260724/26813547.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Alpha+Cognition+Inc.+++++++++++++++++++Filed+by%3A+Opaleye+Management+Inc./26813547.html Fri, 24 Jul 2026 16:05:00 -0400 ACOG O.40625266 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Alpha+Cognition+Inc.+++++++++++++++++++Filed+by%3A+Opaleye+Management+Inc./26813547.html si-local-file:///var/storage/secattach/20260724/26813547.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Alpha+Cognition+Inc.+++++++++++++++++++Filed+by%3A+Opaleye+Management+Inc./26813547.html Fri, 24 Jul 2026 16:05:00 -0400 ACOG O.40625266 http://www.streetinsider.com/Press+Releases/Alpha+Cognition+to+Participate+in+Panel+Discussion+at+the+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26755438.html <p> VANCOUVER, British Columbia &amp; DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced Michael McFadden, Chief Executive Officer, will participate in the Late-Stage &amp; Commercial CNS Small Cap panel discussion during the upcoming B. Riley Securities Mind, Muscle &amp; Vision Summit, taking place July 16th in Boston, Massachusetts. The panel discussion will be held from 3:10 p.m. to 3:50 p.m. ET.</p><p>For further information regarding this event or to schedule a 1x1 meeting during the summit, please reach out to http://www.streetinsider.com/Press+Releases/Alpha+Cognition+to+Participate+in+Panel+Discussion+at+the+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26755438.html Fri, 10 Jul 2026 08:30:00 -0400 A.31492554 ACOG O.20507970 O.40625266 http://www.streetinsider.com/Press+Releases/Alpha+Cognition+to+Participate+in+Panel+Discussion+at+the+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26755438.html <p> VANCOUVER, British Columbia &amp; DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced Michael McFadden, Chief Executive Officer, will participate in the Late-Stage &amp; Commercial CNS Small Cap panel discussion during the upcoming B. Riley Securities Mind, Muscle &amp; Vision Summit, taking place July 16th in Boston, Massachusetts. The panel discussion will be held from 3:10 p.m. to 3:50 p.m. ET.</p><p>For further information regarding this event or to schedule a 1x1 meeting during the summit, please reach out to http://www.streetinsider.com/Press+Releases/Alpha+Cognition+to+Participate+in+Panel+Discussion+at+the+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26755438.html Fri, 10 Jul 2026 08:30:00 -0400 A.31492554 ACOG O.20507970 O.40625266 http://www.streetinsider.com/Press+Releases/Alpha+Cognition+to+Participate+in+Panel+Discussion+at+the+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26755438.html <p> VANCOUVER, British Columbia &amp; DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced Michael McFadden, Chief Executive Officer, will participate in the Late-Stage &amp; Commercial CNS Small Cap panel discussion during the upcoming B. Riley Securities Mind, Muscle &amp; Vision Summit, taking place July 16th in Boston, Massachusetts. The panel discussion will be held from 3:10 p.m. to 3:50 p.m. ET.</p><p>For further information regarding this event or to schedule a 1x1 meeting during the summit, please reach out to http://www.streetinsider.com/Press+Releases/Alpha+Cognition+to+Participate+in+Panel+Discussion+at+the+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26755438.html Fri, 10 Jul 2026 08:30:00 -0400 A.31492554 ACOG O.20507970 O.40625266 http://www.streetinsider.com/Press+Releases/Alpha+Cognition+to+Participate+in+Panel+Discussion+at+the+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26755438.html <p> VANCOUVER, British Columbia &amp; DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced Michael McFadden, Chief Executive Officer, will participate in the Late-Stage &amp; Commercial CNS Small Cap panel discussion during the upcoming B. Riley Securities Mind, Muscle &amp; Vision Summit, taking place July 16th in Boston, Massachusetts. The panel discussion will be held from 3:10 p.m. to 3:50 p.m. ET.</p><p>For further information regarding this event or to schedule a 1x1 meeting during the summit, please reach out to http://www.streetinsider.com/Press+Releases/Alpha+Cognition+to+Participate+in+Panel+Discussion+at+the+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26755438.html Fri, 10 Jul 2026 08:30:00 -0400 A.31492554 ACOG O.20507970 O.40625266